Cardiac Amyloidosis: The Diagnosis Being Missed in Men Over 60, and Why TTR Type Changes the Treatment Completely

2. What It Is

Cardiac amyloidosis is an infiltrative cardiomyopathy caused by deposition of misfolded proteins in the myocardial extracellular matrix. The deposited protein, called amyloid, disrupts myocardial architecture, causes ventricular stiffness, conduction abnormalities, and ultimately restrictive cardiomyopathy and heart failure.

There are two clinically dominant forms:

ATTR Amyloidosis (Transthyretin)

Transthyretin (TTR) is a transport protein produced primarily by the liver, responsible for carrying thyroxine and retinol. When TTR misfolds, it forms amyloid fibrils that deposit in the heart, nerves, and other organs.

Wild-type ATTR (wtATTR or ATTRwt): The TTR gene is normal but TTR protein misfolds with aging. This is a disease of aging, predominantly male patients, with a mean age of diagnosis above 75. It is significantly underdiagnosed; autopsy series suggest ATTRwt is present in 13-25% of patients over 80 with heart failure 5 / Solid .

Hereditary ATTR (hATTR or ATTRv): Autosomal dominant mutation in the TTR gene. The most clinically significant variant in the United States is Val122Ile (V122I), predominantly in Black Americans (3-4% carrier frequency). The Val30Met variant is the most common worldwide, found predominantly in Portugal, Sweden, and Japan. hATTR typically presents at a younger age (50s-60s) and often involves peripheral neuropathy in addition to cardiomyopathy.

AL Amyloidosis (Immunoglobulin Light Chain)

AL amyloidosis is caused by a plasma cell dyscrasia (most often without meeting full myeloma criteria, but sometimes accompanying multiple myeloma). Clonal plasma cells produce abnormal immunoglobulin light chains that misfold into amyloid fibrils depositing in the heart, kidneys, liver, and nerves. AL cardiac amyloidosis progresses faster than ATTR, carries worse prognosis, and is treated fundamentally differently (chemotherapy targeting the plasma cell clone, not TTR-stabilizing drugs). The median survival without treatment was 6-12 months from cardiac involvement 5 / Solid .

The distinction between ATTR and AL amyloidosis is essential because their treatments are completely different.

3. The Mechanism

TTR misfolding and fibril deposition

Transthyretin circulates as a tetramer (four protein subunits). The tetramer is stable; its subunits are not. When the tetramer dissociates into monomers, the monomers can misfold, aggregate into oligomers, and ultimately form insoluble amyloid fibrils. The V122I mutation destabilizes the tetramer, accelerating dissociation at lower temperatures and concentrations. Wild-type TTR tetramers also dissociate with aging due to accumulated post-translational modifications.

Amyloid fibrils are arranged in the myocardium between cardiomyocytes in an interstitial, perimesodermal, and perivascular pattern. They increase myocardial stiffness directly (mechanical effect) and may also be directly cardiotoxic (oligomeric forms of amyloid before they form mature fibrils may cause calcium dysregulation and cardiomyocyte death). This dual mechanism of restriction and direct toxicity explains the progressive nature of the disease.

Cardiac consequences

The stiff, infiltrated ventricle:

• Restrictive physiology: High filling pressures at low volumes. The classic hemodynamic profile is equalization of diastolic pressures across all four chambers (a “square root” sign on catheterization, similar to constrictive pericarditis). PCWP elevation. Reduced stroke volume despite preserved or mild-to-moderately reduced EF.
• Biventricular involvement: The RV is often thickened and dysfunctional in ATTR-CM, contributing to right-sided congestion.
• Atrial disease: Amyloid deposits in the atria cause atrial failure (loss of effective atrial contraction) and atrial fibrillation. Importantly, atrial amyloid impairs the ability to form thrombus normally in the appendage, creating a paradoxically raised stroke risk even in the absence of measurable AF.
• Conduction disease: Amyloid infiltrates the AV node and bundle of His, causing progressive AV block, bundle branch block, and need for permanent pacemaker. Pacemaker implantation in a patient with progressive conduction disease and unexplained left ventricular hypertrophy (LVH) should trigger evaluation for amyloidosis.
• Low-voltage ECG: The classic ECG finding in cardiac amyloidosis is discordance between the thick ventricle on echo and the low-voltage on ECG. Normal voltage with LVH would be expected; amyloid replaces conductive myocardium with electrically inert amyloid, reducing voltage despite increased wall thickness. This discordance is a red flag.

4. How We Diagnose

The diagnostic revolution in ATTR-CM is the non-invasive nuclear scan, which has eliminated the need for endomyocardial biopsy in most ATTR cases.

Red Flags: the amyloidosis clinical syndrome

Clinical triggers that should prompt evaluation:

• heart failure with preserved ejection fraction (HFpEF) in a patient over 65, especially male, with LVH on echo
• “Carpal tunnel syndrome” (bilateral, often requiring surgery, years before cardiac diagnosis; TTR deposits in the carpal tunnel cause median nerve compression)
• Lumbar spinal stenosis in older men with HF
• Low-flow, low-gradient aortic stenosis (amyloid coexists with AS in 15% of transcatheter aortic valve replacement [TAVR] patients)
• Bilateral wrist pain, lower extremity neuropathy, autonomic dysfunction
• New-onset AF with rapid ventricular response in older patients with unexplained LVH
• Low QRS voltage on ECG with echocardiographic LVH
• Third-generation troponin elevation that is chronic rather than acute

Echocardiography

Classic findings: concentrically thickened ventricle, biventricular wall thickening, granular or sparkling myocardial texture (echo-bright appearance), diastolic dysfunction with restrictive filling pattern, right heart involvement, interatrial septum thickening, pericardial effusion, dilated atria, and reduced longitudinal strain with relative apical sparing (the “cherry on top” pattern on strain imaging; base and mid-segments show reduced longitudinal strain while the apex is preserved) 5 / Solid .

Cardiac MRI with parametric mapping

CMR with late gadolinium enhancement shows a global, subendocardial-predominant or transmural LGE pattern, which is distinct from ischemic (coronary territory distribution) or myocarditic (midwall, epicardial) patterns. T1 mapping shows markedly raised native T1 values and raised extracellular volume (ECV) fraction, reflecting amyloid expansion of the extracellular matrix. CMR is the most sensitive imaging tool for amyloidosis staging 5 / Solid .

Tc-99m PYP scintigraphy (nuclear bone scan)

This is the diagnostic turning point. Tc-99m pyrophosphate (and Tc-99m DPD, used in Europe) binds to calcium in amyloid fibrils, producing intense cardiac uptake in ATTR-CM. The scan is performed with planar images at 1 and 3 hours and with SPECT/CT for localization.

Grading: 0 = no cardiac uptake; 1 = faint; 2 = equal to rib uptake; 3 = greater than rib uptake. Grade 2 or 3 cardiac uptake with heart-to-contralateral (H/CL) ratio above 1.5 at 3 hours, in the absence of a monoclonal protein, has 100% specificity for ATTR-CM in several validation studies 5 / Solid .

Critical distinction: If the PYP scan is positive (suggesting ATTR), the clinician MUST rule out AL amyloidosis before concluding ATTR, because AL can occasionally produce positive PYP uptake, and treating AL with a TTR stabilizer while missing the plasma cell clone is fatal. The AL exclusion workup requires serum and urine protein electrophoresis with immunofixation, and serum free light chains. If all are negative, tissue biopsy is not required for ATTR diagnosis.

Tissue biopsy

Abdominal fat pad biopsy (sensitivity approximately 80% for ATTR), rectal biopsy, or endomyocardial biopsy (highest sensitivity, gold standard but invasive). Biopsy is required for AL diagnosis to confirm amyloid deposition and identify the fibril protein type by mass spectrometry. Congo red staining shows apple-green birefringence under polarized light (the classic finding).

5. The Evidence

ATTR-ACT: tafamidis (2018)

The ATTR-ACT trial enrolled 441 patients with ATTR-CM (both wild-type and hereditary) and randomized them to tafamidis 80 mg, tafamidis 20 mg, or placebo for 30 months 5 / Solid .

Results: Combined tafamidis groups reduced all-cause mortality by 29.5% versus placebo (HR 0.70, 95% CI 0.51-0.96, p < 0.001 for all-cause mortality alone at 30 months). Tafamidis also reduced hospitalization rate and improved quality of life (KCCQ). This was the first mortality-reducing therapy ever demonstrated for any form of cardiac amyloidosis.

Tafamidis (Vyndaqel, tafamidis meglumine, and Vyndamax, tafamidis free acid) stabilizes the TTR tetramer, preventing dissociation and fibril formation. It does not dissolve existing amyloid deposits; it slows or halts further deposition.

The 30-month survival benefit: Kaplan-Meier survival curves diverged at approximately 18 months. Earlier initiation is likely to produce greater benefit; patients with preserved NYHA Class I-II function at baseline had greater absolute benefit than those already in NYHA III-IV.

ATTR-ACT long-term extension (2020)

Maurer MS, et al., NEJM 2020 (10.1056/NEJMoa2009637): Among patients who continued on tafamidis after the initial 30-month trial, those who received tafamidis throughout the extension had persistently lower mortality than those who received placebo initially and were crossed over to tafamidis at 30 months. The early-start benefit was durable; late crossover produced improvement but not equivalent outcomes 5 / Solid . This reinforces the importance of early diagnosis and early treatment initiation.

HELIOS-B: vutrisiran (2024)

The HELIOS-B trial enrolled 655 patients with ATTR-CM and randomized them to vutrisiran (an RNA interference agent, Amvuttra) versus placebo 5 / Solid . Vutrisiran reduces hepatic TTR production by silencing the mRNA encoding TTR using RNAi technology, delivered subcutaneously every three months. At 42 months, vutrisiran reduced all-cause mortality and recurrent cardiovascular events by 28% (HR 0.72, 95% CI 0.56-0.93, p = 0.01).

Vutrisiran does not stabilize the tetramer; it reduces the amount of TTR produced. This approach eliminates both wild-type and mutant TTR equally. It is the first subcutaneous RNAi therapy approved for cardiac amyloidosis (FDA approval 2024).

The HELIOS-A trial had previously shown patisiran (intravenous RNAi predecessor) reduces polyneuropathy progression in hATTR with cardiac involvement 5 / Solid .

APOLLO-B: patisiran for ATTR-CM with polyneuropathy (2022)

APOLLO-B enrolled ATTR-CM patients (with and without polyneuropathy) and showed patisiran IV reduced the primary outcome of 6-minute walk distance decline and KCCQ composite 4 / Promising .

CRISPR-based approaches: early data

NTLA-2001 (intellia therapeutics), a CRISPR-Cas9 gene editing approach to permanently silence the TTR gene in hepatocytes, showed an 87% reduction in serum TTR levels in the first phase 1 data published in 2021 3 / Early . Clinical outcome trials are ongoing. If durable, CRISPR-based TTR knockdown would represent a one-time treatment eliminating the need for chronic drug therapy.

AL amyloidosis treatment

AL amyloidosis treatment targets the plasma cell clone producing the toxic light chains. The modern approach:

• Transplant-eligible patients: Autologous stem cell transplantation (ASCT) following high-dose melphalan offers the possibility of complete hematologic response and amyloid regression.
• Non-transplant eligible: Daratumumab (anti-CD38 antibody, Darzalex) plus bortezomib (proteasome inhibitor) plus dexamethasone (Dara-VD), the current standard-of-care regimen. The ANDROMEDA trial showed Dara-VD produced complete hematologic response in 53% of patients (versus 18% for bortezomib-based standard therapy alone) 5 / Solid .

6. The Patient Experience

The patient with ATTR-CM has often been on a long diagnostic odyssey. The average time from symptom onset to diagnosis of ATTR-CM in published series is 2-5 years, and the diagnostic delay is particularly pronounced in Black Americans carrying the V122I variant 5 / Solid ).

The non-cardiac clues are retrospectively obvious: bilateral carpal tunnel release several years prior; difficulty walking on uneven surfaces (peripheral neuropathy); autonomic symptoms (orthostatic hypotension, constipation, sexual dysfunction in hATTR). The ATTR-CM story often assembles itself backward once the diagnosis is made.

The medication landscape:

• Tafamidis 61 mg (Vyndamax) or 80 mg (Vyndaqel) taken orally once daily. The cost was approximately $225,000 per year at launch in 2019. With copay assistance programs, patient out-of-pocket costs have been reduced substantially for insured patients. For uninsured and underinsured patients in Illinois, access remains a significant barrier. The manufacturer (Pfizer) operates a patient assistance program; prior authorization requirements vary by insurer.
• Vutrisiran (Amvuttra) is dosed as a subcutaneous injection every three months. The administration logistics are manageable; the cost is similarly high.

For patients with heart failure symptoms, standard ADHF management applies: diuretics for congestion, management of atrial fibrillation. Critically: ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers (ARBs) are often poorly tolerated in cardiac amyloidosis because the stiff, restrictive ventricle is preload-dependent, and renin-angiotensin-aldosterone system (RAAS) blockade reduces filling pressure below the threshold needed to maintain adequate stroke volume. Beta-blockers are similarly problematic because the heart in amyloidosis relies on heart rate to maintain cardiac output (since stroke volume is fixed). This is the opposite of heart failure with reduced ejection fraction (HFrEF) physiology, and it means that the standard HFrEF protocol can worsen hemodynamics in advanced cardiac amyloidosis.

Anticoagulation: the intracardiac thrombus risk in ATTR-CM is raised even without documented atrial fibrillation, because amyloid deposits impair atrial contractile function and reduce appendage emptying velocity. There is no RCT evidence for anticoagulation in ATTR-CM without AF. Many amyloid cardiomyopathy specialists anticoagulate ATTR-CM patients with documented atrial failure on the basis of low appendage emptying velocity on TEE, but this is center-specific practice 3 / Early .

7. Decisions and Trade-Offs

When to start tafamidis versus watchful waiting

The ATTR-ACT benefit was clearest in NYHA Class I-II patients. Patients in NYHA III-IV had less benefit, possibly because too much amyloid was already deposited. The clinical imperative: diagnose early and start tafamidis early. A patient with asymptomatic or mildly symptomatic ATTR-CM (discovered on an incidental echo showing LVH and diastolic dysfunction, before NYHA Class II symptoms develop) represents the ideal treatment scenario.

The 2022 AHA/ACC guidelines recommend tafamidis for symptomatic ATTR-CM (NYHA Class I-III) to reduce mortality and cardiovascular hospitalization 5 / Solid .

Genetic testing implications

A patient diagnosed with hATTR (V122I or other variant) has a 50% risk of passing the variant to each child (autosomal dominant). Genetic counseling and cascade screening of first-degree relatives is a standard recommendation and a conversation that requires clinical sensitivity. A sibling who tests positive for V122I at age 50 and has a normal echo should still be enrolled in surveillance echocardiography every 2-3 years, because disease penetrance increases with age and early treatment initiation produces the best outcomes.

Device therapy in ATTR-CM

Pacemaker: progressive AV block is common; many ATTR-CM patients require permanent pacing. Once a pacemaker is placed, a concurrent ICD discussion is warranted, but ICD evidence in ATTR-CM is not well-established. The arrhythmia risk in ATTR-CM is primarily from atrial disease and conduction block rather than ventricular tachyarrhythmia; the HATCH score helps stratify who needs ICD.

ICD: the sudden cardiac death risk in ATTR-CM is lower than HFrEF cardiomyopathy because the primary mechanism of death is pump failure, not VF/VT. ICD implantation in ATTR-CM should be individualized; it is not routinely recommended unless EF falls below 35% and life expectancy exceeds one year.

Transplant candidacy

Some patients with ATTR-CM are candidates for heart-liver transplant (simultaneous transplantation removes the source of mutant TTR from the liver and replaces the diseased heart). This is primarily relevant for young hATTR patients with severe cardiac disease and minimal extracardiac involvement. The waiting list and surgical complexity limit this to a small number of cases per year at specialized centers. The Bluhm Cardiovascular Institute at Northwestern Memorial Hospital (Chicago) is a recognized ATTR center.

Clinical Synthesis

Cardiac amyloidosis is the most underdiagnosed major cardiac condition in medicine. The diagnostic revolution of the past decade (PYP scan, CMR, mass spectrometry fibril typing) now makes ATTR-CM diagnosable without tissue biopsy in most cases. The therapeutic revolution (tafamidis, vutrisiran, and the approaching CRISPR era) makes it treatable. The access revolution has not yet happened.

The racial disparity is stark. Black Americans carry the V122I TTR variant at 3-4% prevalence. The variant causes hereditary ATTR-CM that presents in the 50s and 60s. For decades, it was called “rare” because Black patients with heart failure were not systematically screened for it. Screening requires awareness, a PYP scan, and access to a cardiologist familiar with the diagnosis.

A structured cardiovascular assessment specifically incorporates the amyloidosis screening protocol: for any patient over 60 with HFpEF pattern on echocardiography, or for any Black patient over 50 with LVH and diastolic dysfunction, the protocol includes evaluation for amyloidosis triggers (carpal tunnel history, neuropathy history, family history, ECG voltage discordance). This is not a population-level screening program; it is a targeted clinical diagnostic step that currently does not happen systematically.

For patients diagnosed with ATTR-CM, structured remote monitoring provides the serial monitoring required: quarterly echocardiography and biomarker tracking, medication access navigation (tafamidis prior authorization, patient assistance program enrollment), and connection to tertiary amyloid centers when escalation is needed.

The retired postal worker from the South Side of Chicago spent five years with “diastolic dysfunction” before his V122I-driven ATTR-CM was identified. He lost years of potential tafamidis therapy. His children have been tested. One son carries the variant; his echo shows LVH but no symptoms. He started tafamidis at 54.

That son will not have the same story.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.